What Is Urumin? Definition and What Research Reports

Definition

Urumin is the name assigned to a short, naturally occurring host defense peptide — also called an antimicrobial or innate immune peptide — that was isolated from amphibian skin secretions and characterised for antiviral activity. In the 2017 report that introduced the term, researchers described urumin as a peptide isolated from the skin secretion of the South Indian frog Hydrophylax bahuvistara that was virucidal for human influenza A viruses bearing H1 hemagglutinin (PMID 28423338). In peptide vocabulary, "urumin" functions as a proper name for one specific sequence, in the same way that "magainin" or "LL-37" names a particular host defense peptide rather than a category.

What Class of Molecule It Is

Host defense peptides are short amino acid chains produced by the innate immune systems of many organisms, including amphibians, insects and mammals. They are generally studied for direct antimicrobial or antiviral activity and for their interactions with membranes and pathogen surface proteins. Urumin sits in this family. It is not a metabolic or growth-related peptide, not a hormone analogue, and not a secretagogue; grouping it with peptides studied for body-composition or recovery endpoints would be a category error.

Amphibian skin has long been a source of such molecules because frog cutaneous glands secrete complex peptide mixtures as a first line of defense. Screening those secretions is a standard discovery route, and the 2017 work followed that route, with researchers reporting that urumin emerged from a library of peptides derived from frog skin secretion (PMID 28423338).

Quick reference

How the Term Is Used in Peptide Research

Three usages dominate. First, as a named discovery: papers cite urumin when tracing where a particular antiviral mechanism was first described. Second, as a class example: reviews of innate immune peptides use recently characterised molecules to illustrate how amphibian and other natural peptides are screened, sequenced and tested. A 2020 review surveyed selected new antimicrobial innate immune peptides described between 2015 and 2019 and placed such discoveries in a shared pharmacological and structural context (PMID 33092508). Third, as a search term in databases of antimicrobial peptide sequences, where entries record the source organism, sequence length and reported activity spectrum.

Outside of these uses, the term has no established meaning. Urumin is not a compounded medicine, is not an approved drug product in the cited literature, and the papers below do not describe human administration of any kind.

What the Published Literature Reports

The primary source is a 2017 paper in Immunity. In it, researchers reported that urumin was specifically effective against human influenza A viruses carrying H1 hemagglutinin, and that the peptide destroyed the structural integrity of influenza virions as visualised by transmission electron microscopy (PMID 28423338). The same study reported that the peptide targeted the conserved stalk region of H1 hemagglutinin — the part of the surface protein that varies least between strains — rather than the more variable head domain (PMID 28423338). In an animal model, the study reported that urumin protected naive mice from otherwise lethal influenza infection (PMID 28423338).

Two limits of that report are worth stating plainly. The activity described was subtype-restricted: the reported effect was tied to H1 hemagglutinin-bearing viruses rather than to influenza generally (PMID 28423338). And the work was preclinical — cell-based assays, electron microscopy and a mouse challenge model — so no human efficacy or human dosing information exists in the cited record.

Subsequent literature has mostly treated urumin as part of a broader wave of innate immune peptide discovery. The 2020 review of antimicrobial innate immune peptides described during 2015–2019 reported on how such peptides were identified, how their structures were characterised, and which pathogen classes they were tested against (PMID 33092508).

Urumin Tolerability in Cell and Animal Work: What Studies Report

The cited literature contains no human safety data. Within the 2017 laboratory work, researchers reported that the peptide was non-cytotoxic to human red blood cells and to primary human tracheal epithelial cells under the conditions tested (PMID 28423338). That is a narrow in-vitro observation about two cell types in one experimental setting; it is not a systemic safety profile, and it says nothing about tolerability, immunogenicity or pharmacokinetics in people. No adverse-event tables, no dose-limiting toxicity findings and no long-term exposure data appear in any of the papers cited on this page.

Where Peptide Antivirals Sit in Current Research

Antiviral peptide research has increasingly explored scaffolds that present multiple peptide copies at once, on the reasoning that multivalent binding can improve potency against virion surfaces. A 2025 preprint reported that hybrid peptide–DNA nanomaterials produced potent and broad-spectrum virus neutralization in laboratory testing (PMID 40777507). That report describes a general platform approach; its title and abstract scope do not establish urumin as a component of the materials tested, and this page makes no such claim. It is cited here only to indicate the direction of the surrounding field, and — as a preprint — it had not completed peer review at the time of writing.

What the Literature Does Not Establish

• No human data. None of the cited papers report administration of urumin to humans, so there is no established human dose, route, schedule or efficacy estimate.
• No approved product. The cited record describes research findings, not a marketed medicine.
• No broad antiviral claim. The reported virucidal activity was tied to H1 hemagglutinin-bearing influenza viruses in the 2017 study (PMID 28423338), not to viruses in general.
• No formulation or stability guidance. Delivery, stability and manufacturing questions are not addressed in the cited abstracts.

Related Glossary Terms

• Host defense peptide (HDP): the broader class to which urumin belongs; peptides produced as part of innate immunity.
• Antimicrobial peptide (AMP): a largely overlapping term, used in the 2020 review of peptides described during 2015–2019 (PMID 33092508).
• Hemagglutinin (HA) stalk: the conserved region of the influenza surface protein that the 2017 study reported as urumin's target (PMID 28423338).
• Virucidal: describing direct inactivation of virus particles, as distinct from blocking replication inside a cell.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question, and note that the compounds described here are discussed strictly as subjects of published research.

References

• An Amphibian Host Defense Peptide Is Virucidal for Human H1 Hemagglutinin-Bearing Influenza Viruses (Immunity, 2017)
• Spotlight on the Selected New Antimicrobial Innate Immune Peptides Discovered During 2015-2019 (Current Topics in Medicinal Chemistry, 2020)
• Hybrid peptide DNA nanomaterials enable potent and broad-spectrum virus neutralization (bioRxiv preprint, 2025)